Skip to content

Randomized controlled trial for the effect of transcutaneous electrical acupoint stimulation combined with auricular acupoints on sexual development of peripheral precocious puberty girls

Randomized controlled trial for the effect of transcutaneous electrical acupoint stimulation combined with auricular acupoints on TCM syndrome and sexual development of peripheral precocious puberty girls

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800020432
Enrollment
Unknown
Registered
2018-12-29
Start date
2019-01-01
Completion date
Unknown
Last updated
2020-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral precocious puberty

Interventions

treatment group:transcutaneous electrical acupoint stimulation combined with auricular acupoints and health education
control group:health education

Sponsors

Beijing Municipal Administration of Hospitals
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
3 Years to 8 Years

Inclusion criteria

Inclusion criteria: (1) Meet the diagnostic criteria of peripheral precocious puberty; (2) Girls before the age of 8 have secondary sexual characteristics such as breast development and pubic hair premature appearance; (3) In gonadotropin releasing hormone (GnRH) stimulation test, the peak value of LH was less than 3.3-5.0 IU/L and the peak value of LH/FSH was less than 0.6; (4) Parents agree and sign informed consent; (5) Previous treatment without any medication or intervention

Exclusion criteria

Exclusion criteria: (1) Central precocious puberty; (2) heterosexual precocious puberty in girls; (3) precocious puberty caused by gonadal tumors and adrenal diseases; (4) suspicious chromosomal abnormalities or hereditary diseases with special appearance, skin abnormalities, growth and development abnormalities; (5) It does not meet the inclusion criteria and can not adhere to the treatment course; (6) Participants in other clinical trials.

Design outcomes

Primary

MeasureTime frame
Serum sex hormones;breast Tanner stage;

Secondary

MeasureTime frame
Gynecological pelvic ultrasonography;TCM symptoms;BMI;

Countries

China

Contacts

Public ContactLiu Lili

Beijing Jishuitan Hospital

liulili2005@126.com+86 010-58516903

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026